TITLE

Out of step on AIDS

PUB. DATE
June 1991
SOURCE
New Scientist;6/29/91, Vol. 130 Issue 1775, p13
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on the inequalities between industrialized and developing countries in managing AIDS. Inability of developing to gain access to antiviral drug zidovudine; Claim that HIV infection is difficult to transmit and relatively stoppable; Failure of biotechnology companies to provide low-cost AIDS drugs for developing countries.
ACCESSION #
10491301

 

Related Articles

  • An AIDS Drug-Price War. Guterl, Fred; Margolis, Mac; Mazumdar, Sudip; Masland, Tom; Suterwalla, Shehnaz // Newsweek (Atlantic Edition);02/19/2001 (Atlantic Edition), Vol. 137 Issue 8, p53 

    Discusses the decision of Indian drugmaker Cipla to cut prices on its anti-AIDS drugs in developing countries. The effect which this is having on the worldwide pharmaceutical industry; Cipla's distribution of the drugs through the organization Medecins sans frontieres; Patent-law issues.

  • Subsidizing HIV/AIDS Drugs: An Overview. Farrell, Courtney; English, Marlanda // Points of View: Subsidizing HIV/AIDS Drugs;3/1/2016, p1 

    The article examines the debate over the provision of subsidies for antiretroviral drug treatment by the U.S. government. The prices of antiretroviral drugs are lower in developing countries than in the U.S. and Western Europe. Moreover, generic versions of such drugs may be produced in...

  • A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. Waning, Brenda; Diedrichsen, Ellen; Moon, Suerie // Journal of the International AIDS Society;2010, Vol. 13 Issue 1, p1 

    Background: Indian manufacturers of generic antiretroviral (ARV) medicines facilitated the rapid scale up of HIV/ AIDS treatment in developing countries though provision of low-priced, quality-assured medicines. The legal framework in India that facilitated such production, however, is changing...

  • The Spirit of TRIPS and the Importation of Medicines Made under Compulsory License after the August 2003 TRIPS Council Agreement. Fayerman, Jessica J. // Northwestern Journal of International Law & Business;Fall2004, Vol. 25 Issue 1, p257 

    Focuses on the issue concerning the harmonization of pharmaceutical laws since the drafting of the Agreement on Trade-Related Aspects of Intellectual Property Rights in developing countries. Importance of the uniform world intellectual property laws for the promotion of free and balanced trade...

  • Falling Objects.  // Pharmaceutical Executive;Apr2001, Vol. 21 Issue 4, p34 

    Deals with the decision of pharmaceutical firms Merck, Bristol-Myers Squibb and BMS to cut the price of AIDS treatments in developing countries. Price cuts implemented by Merck on its antiretrovirals in developing countries; Price of the AIDS drugs offered by Cipla, a generic medicine company...

  • AIDS drug prices to drop in developing nations.  // Medical Marketing & Media;Jul98, Vol. 33 Issue 7, p26 

    Reports on the plan of drug companies to reduce the prices of their acquired immune deficiency syndrome (AIDS) drugs in developing nations. Estimated amount which the drugs will be reduced by; How much will the Glaxo Wellcome company reduce the brands AZT and 3TC by; Names of other drug companies.

  • Glaxo cuts drug prices for developing countries. Wise, Jacqui // BMJ: British Medical Journal (International Edition);06/23/2001, Vol. 322 Issue 7301, p1510 

    Reports that the pharmaceutical company GlaxoSmithKline will lower the cost of its antimalarial and newer HIV and AIDS drugs to developing countries. Details of the announcement, including which countries will be eligible; Response by the World Health Organization (WHO) and aid charities;...

  • Cut-Rate AIDS. Golden, Frederic // Time International (South Pacific Edition);3/19/2001, Issue 11, p56 

    Reports on the need for lower prices for combination-drug therapy for AIDS disease in developing countries. Efforts of pharmaceutical companies to avoid cutting prices and keeping generic copies of their drugs out of South Africa; Decision of Merck and other drug companies to cut prices for...

  • Cut-Rate AIDS. Golden, Frederic // Time;3/19/2001, Vol. 157 Issue 11, p68 

    Reports on the need for lower prices for combination-drug therapy for AIDS disease in developing countries. Efforts of pharmaceutical companies to avoid cutting prices and keeping generic copies of their drugs out of South Africa; Decision of Merck and other drug companies to cut prices for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics